OCTA-RVD: Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Sponsor
Johns Hopkins University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04505618
Collaborator
National Eye Institute (NEI) (NIH)
1,050
1
4
71
14.8

Study Details

Study Description

Brief Summary

This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: Swept-Source OCT Angiography
  • Device: Spectral-Domain OCT Angiography
  • Device: Fundus Imaging
  • Device: Axial Length Measurement Device
N/A

Detailed Description

The objective of this study is to perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Subjects will be identified from healthy subjects (seen for screening eye exams) and diseased subjects undergoing standard-of-care treatment or screening at eye clinic locations. The study population will include subjects with retinal vascular disease including but not limited to diabetic retinopathy, hypertension, retinal vein/arterial occlusion, and macular degeneration. Subjects who are enrolled will undergo non-invasive, minimal risk, FDA approved diagnostic imaging procedures to identify vascular changes.

The study methods will include retrospective review and collection of clinically approved imaging data that is obtained through standard-of-care methods for subjects who meet inclusion and exclusion criteria. Subjects who are identified in this manner will be asked to participate in a prospective study by each clinical study site.

The study end-points include the correlation of diagnostic imaging findings from OCT based images with fundus photographs, clinical disease stage and visual acuity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1050 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Screening
Official Title:
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
Actual Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Controls

Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.

Device: Swept-Source OCT Angiography
Non-invasive, minimal risk, ocular imaging study
Other Names:
  • SS-OCTA
  • Device: Spectral-Domain OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SD_OCTA
  • Device: Fundus Imaging
    Non-invasive, minimal risk, ocular imaging study

    Device: Axial Length Measurement Device
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • IOL Master
  • Other: Diabetics with and without Diabetic Retinopathy Only

    Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.

    Device: Swept-Source OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SS-OCTA
  • Device: Spectral-Domain OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SD_OCTA
  • Device: Fundus Imaging
    Non-invasive, minimal risk, ocular imaging study

    Device: Axial Length Measurement Device
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • IOL Master
  • Other: Hypertension Only

    Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.

    Device: Swept-Source OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SS-OCTA
  • Device: Spectral-Domain OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SD_OCTA
  • Device: Fundus Imaging
    Non-invasive, minimal risk, ocular imaging study

    Device: Axial Length Measurement Device
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • IOL Master
  • Other: Diabetics w/ or w/o Diabetic Retinopathy & Hypertension

    Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.

    Device: Swept-Source OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SS-OCTA
  • Device: Spectral-Domain OCT Angiography
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • SD_OCTA
  • Device: Fundus Imaging
    Non-invasive, minimal risk, ocular imaging study

    Device: Axial Length Measurement Device
    Non-invasive, minimal risk, ocular imaging study
    Other Names:
  • IOL Master
  • Outcome Measures

    Primary Outcome Measures

    1. Correlation of Imaging [5 years]

      Correlation of diagnostic imaging findings (vessel skeleton density) from OCT based images with disease stage

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Exclusion Criteria:
    • Both subjects with diseases and controls:

    • Children (age<18)

    • Pregnant females

    • Developmentally delayed subjects

    • Subjects unable to provide informed consent

    • Inability to cooperate with tests and study instructions

    • Images with motion artifact or signal strength < 7

    • History of glaucoma

    • History of age-related macular degeneration

    • History of any visually significant eye disease

    • History of proliferative diabetic retinopathy

    • History of any inflammatory disease

    • History of heart disease

    • History of thyroid disease.

    • Additional criteria for controls:

    • History of any type of Diabetes Mellitus

    • History of any type of Hypertension

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wilmer Eye Institute Baltimore Maryland United States 21287

    Sponsors and Collaborators

    • Johns Hopkins University
    • National Eye Institute (NEI)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Johns Hopkins University
    ClinicalTrials.gov Identifier:
    NCT04505618
    Other Study ID Numbers:
    • IRB00276904
    • R01EY030564
    First Posted:
    Aug 10, 2020
    Last Update Posted:
    Aug 11, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 11, 2022